Gilead Sciences, Inc. (NASDAQ: GILD) announced on October 22, 2026, that it had entered into a definitive agreement to acquire an investigational oral interleukin-23 receptor inhibitor programme, including lead candidate HCXT-2001, from privately held PepStar Therapeutics Limited for $1.275 billion in upfront cash consideration. The transaction gives Gilead worldwide rights to the Phase 1 oral macrocyclic peptide programme, which is being developed for potential applications in immune-mediated inflammatory diseases, including inflammatory bowel disease. The acquisition remains subject to customary closing conditions and is expected to be completed during the fourth quarter of 2026.
The transaction represents a substantial commitment to an early-stage medicine that has not yet established efficacy in patients with ulcerative colitis or Crohn’s disease. Rather than acquiring a commercially validated treatment, Gilead is purchasing a development programme targeting an immunological pathway already supported by successful biologic therapies. Its investment suggests that the company sees considerable potential in translating established IL-23 biology into an orally administered treatment.
The agreement also follows encouraging Phase 2 results for Gilead’s internally developed oral integrin inhibitor, emvistegrast. By combining drugs that target different components of intestinal inflammation, Gilead hopes to create future treatment options that may offer alternatives to injectable biologics. However, the scientific rationale for such combinations is distinct from demonstrating their clinical efficacy, and the acquired programme remains several development stages away from potential regulatory approval.
Why is Gilead Sciences paying $1.275 billion for a Phase 1 oral IL-23 receptor inhibitor?
The transaction involves $1.275 billion in upfront cash payable at closing, subject to customary adjustments. Unlike licensing agreements that advertise substantial potential values based on future milestones, the disclosed consideration represents the agreed upfront purchase price for the acquired programme. The payment has not yet been completed, and the transaction’s closing remains conditional.
Gilead expects the acquisition to reduce its GAAP and non-GAAP earnings per share by approximately $0.79 to $0.83 in the fourth quarter of 2026. This expected accounting effect reflects the financial consequences of acquiring development-stage research and intellectual property rather than immediate deterioration in the company’s established commercial operations. Investors will nevertheless need to consider the payment alongside Gilead’s other research investments and acquisition-related expenses.
The price is notable because HCXT-2001 remains in Phase 1 development, where investigations primarily address fundamental questions about safety, tolerability, pharmacokinetics and dose selection. No completed controlled efficacy study in inflammatory bowel disease was disclosed in the October acquisition announcement. The valuation therefore depends heavily on the anticipated utility of the molecule, the rights being acquired and its potential role within a broader inflammation portfolio.
Gilead reported approximately $7.8 billion in total revenue for the second quarter of 2026, demonstrating the financial scale supporting its investment strategy. Its established HIV and liver disease businesses provide substantial commercial revenue, while oncology and inflammation represent areas for continued portfolio development. The HCXT-2001 acquisition should therefore be viewed as part of a wider capital allocation strategy rather than an immediate revenue-generating transaction.
The company has also undertaken substantial acquisitions and research investments during 2026. These commitments increase its exposure to potentially valuable emerging technologies but also create a requirement for disciplined clinical development and portfolio prioritisation. The financial return from HCXT-2001 will depend on its eventual clinical and commercial performance, which cannot be determined from the announced transaction price.
How does HCXT-2001 target the IL-23 pathway involved in inflammatory bowel disease?
HCXT-2001 is an investigational oral macrocyclic peptide designed to inhibit the interleukin-23 receptor, commonly known as IL-23R. Interleukin-23 is a cytokine involved in the regulation of immune responses and has an established role in inflammatory pathways associated with ulcerative colitis, Crohn’s disease and psoriasis. Blocking this signalling pathway can reduce inappropriate immune activation in selected inflammatory conditions.
The therapeutic relevance of IL-23 is supported by several approved monoclonal antibodies targeting components of the pathway. These treatments have established that IL-23 inhibition can produce meaningful clinical benefits in appropriately selected patients. However, their efficacy does not mean that every molecule targeting the pathway will produce equivalent outcomes.
HCXT-2001 is intended to offer a different delivery approach. Rather than requiring injection or infusion, the investigational molecule is being developed as an oral treatment, with an extended half-life that PepStar and Gilead believe could support convenient administration. Gilead has identified once-daily treatment as a potential development objective.
Oral peptide development is technically demanding because peptides can be vulnerable to degradation within the gastrointestinal tract and may have limited absorption. Macrocyclic structures can offer opportunities to modify molecular stability, permeability and receptor-binding properties. Nevertheless, the ability to manufacture an orally administered peptide does not establish that it achieves sufficient and consistent systemic exposure at an acceptable dose.
The extended half-life described in the acquisition announcement provides a possible differentiation factor, but its practical significance remains dependent on human pharmacokinetic evidence. Investigators will need to determine how exposure varies between participants, whether food affects absorption and whether repeated dosing produces predictable pharmacological activity. The eventual safety and efficacy profile must also be evaluated in patients with active inflammatory disease.
What does the existing oral IL-23 inhibitor market reveal about HCXT-2001’s competitive position?
The market has already moved beyond proving that oral IL-23 receptor inhibition is technically possible. Johnson & Johnson obtained United States Food and Drug Administration approval for icotrokinra, marketed as ICOTYDE, on March 17, 2026, for moderate-to-severe plaque psoriasis in eligible adults and adolescents. The approval established an important regulatory and commercial precedent for an oral peptide targeting the IL-23 receptor.
Icotrokinra’s approval does not extend to inflammatory bowel disease, and the clinical requirements for intestinal inflammation differ from those for psoriasis. Nevertheless, the product demonstrates that oral IL-23 receptor inhibition is no longer merely a theoretical pharmaceutical approach. That development changes the competitive context for HCXT-2001.
Gilead will need to establish whether its acquired molecule has characteristics that support a differentiated development strategy. Potential areas include oral exposure, dosing requirements, tolerability, duration of treatment effect and compatibility with other therapies. None of these possible advantages has yet been established through comparative clinical evidence.
The broader inflammatory bowel disease market also includes established injectable therapies targeting IL-23 and other immune pathways. These medicines have generated substantial efficacy and safety data, including evidence relating to remission, endoscopic improvement and long-term disease control. An oral candidate entering clinical development must eventually demonstrate results strong enough to justify its use within that increasingly competitive treatment environment.
Convenience may be commercially relevant, especially for patients who prefer tablets to injections or infusions. However, route of administration is only one component of treatment value. Clinicians and payers will continue to prioritise disease control, tolerability, treatment durability and the ability to address difficult-to-treat populations.
Why could Gilead Sciences combine HCXT-2001 with oral integrin inhibitor emvistegrast?
One of the most distinctive aspects of the acquisition is Gilead’s stated interest in combining HCXT-2001 with emvistegrast, its investigational oral alpha4beta7 integrin inhibitor. The two treatments target different biological processes associated with inflammatory bowel disease. HCXT-2001 is designed to inhibit IL-23 receptor signalling, while emvistegrast targets a pathway associated with immune-cell trafficking into intestinal tissue.
The proposed combination reflects a broader interest in addressing chronic inflammatory disease through complementary mechanisms. Inflammatory bowel disease involves multiple interacting immune processes, and inhibition of a single pathway does not produce sustained remission in every patient. The possibility of targeting both immune signalling and cellular trafficking provides a scientific rationale for investigating a combined approach.
That strategy has gained additional relevance following Gilead’s October 19 disclosure of positive Phase 2 results from the SWIFT study of emvistegrast in moderately to severely active ulcerative colitis. At Week 12, clinical response occurred in 66% of participants receiving the 200 mg dose compared with 37% receiving placebo. Clinical remission was reported in 31% and 8% of participants, respectively.
The findings provide controlled evidence supporting emvistegrast’s further development as a monotherapy. Gilead has indicated that it plans to initiate a Phase 3 monotherapy study in 2027. However, the Phase 2 results do not establish that the drug will be effective when combined with HCXT-2001.
Combination development would introduce additional considerations involving dose selection, pharmacological interactions and the potential consequences of simultaneously modulating separate immune pathways. Investigators would need to determine whether the combination offers incremental benefit over either drug alone and whether that benefit justifies any additional treatment burden or adverse effects. Depending on the development strategy, appropriately controlled studies may be required to establish the contribution of each component.
The combination could also present operational advantages if both medicines can ultimately be administered orally. A fully oral regimen with complementary mechanisms might appeal to selected patients and clinicians, particularly if it offers sustained disease control without infusion or injection requirements. However, the convenience proposition remains conditional on demonstrating adequate efficacy, tolerability and adherence.
What clinical evidence is still missing for HCXT-2001 in ulcerative colitis and Crohn’s disease?
The central limitation of the acquisition is the early maturity of the acquired asset. Gilead has confirmed that HCXT-2001 is in Phase 1 clinical development, but its October announcement did not provide detailed human efficacy results in ulcerative colitis or Crohn’s disease. The safety and efficacy of the molecule have not been established, and it is not approved by any regulatory authority.
Clinical development must first establish that the molecule reaches its intended biological target at exposures that patients can tolerate. Early investigations generally assess adverse events, laboratory measurements, drug concentration profiles and sometimes pharmacodynamic indicators of target engagement. Such findings help determine whether further testing in the intended patient population is justified.
For inflammatory bowel disease, later studies would need to evaluate outcomes extending beyond changes in inflammatory biomarkers. Ulcerative colitis development commonly considers clinical response, clinical remission, endoscopic improvement and histological measures. Crohn’s disease programmes require their own appropriate endpoints, often incorporating symptoms and objective evidence of intestinal inflammation.
The distinction between short-term induction and long-term maintenance treatment is particularly relevant. A medicine that reduces symptoms during an initial treatment period may not necessarily maintain remission over an extended interval. Demonstrating durable control, acceptable long-term tolerability and clinically meaningful benefits will be essential if HCXT-2001 is to compete with established therapies.
Patient selection may also influence the programme’s development prospects. Individuals who have not previously received advanced therapies may respond differently from patients who have experienced inadequate responses to multiple biologics. The company’s eventual trial design will need to address where an additional oral treatment could provide the greatest clinical value.
The acquired programme may also have potential applications in psoriasis and other immune-mediated inflammatory conditions. Those opportunities remain exploratory and should not be confused with established treatment indications. Gilead will need to prioritise disease areas according to biological rationale, clinical evidence and the resources required for development.
How could the acquisition influence Gilead Sciences’ longer-term inflammation business?
Gilead’s established commercial strengths have historically been concentrated in antiviral medicines, particularly HIV and liver disease. Its recent investment activity indicates a willingness to expand into additional therapeutic areas through both internal research and acquisitions. Inflammation offers opportunities involving chronic conditions that often require years of treatment and repeated therapeutic intervention.
However, the competitive environment differs substantially from areas where the company already has entrenched market positions. Several large pharmaceutical companies have established immunology franchises with approved products, extensive clinical datasets and specialist commercial infrastructure. Entering this market successfully will require more than purchasing biologically interesting assets.
The emvistegrast programme provides a potential foundation because it has already produced controlled Phase 2 efficacy findings. HCXT-2001 introduces another mechanism and an opportunity to develop additional monotherapy or combination approaches. The commercial significance of this portfolio will depend on whether Gilead can convert those programmes into effective, appropriately differentiated treatments.
Manufacturing will also become increasingly important if oral peptides advance toward late-stage development. Commercial production requires consistent drug substance quality, formulation performance, stability and compliance with pharmaceutical manufacturing standards. Even a successfully developed molecule can face implementation challenges if production costs, supply reliability or dosing requirements limit practical adoption.
For a potential combination regimen, development complexity could increase further because both components would need to satisfy relevant regulatory and manufacturing requirements. Establishing consistent supply and appropriate controls for each molecule would be necessary before broad commercial availability. Reimbursement decisions would then depend on the final treatment’s clinical value relative to existing alternatives.
The acquisition therefore provides Gilead with strategic flexibility rather than a guaranteed new franchise. A portfolio containing complementary mechanisms may create opportunities for different patient populations and combination strategies. However, investing in multiple approaches also requires decisions about which programmes justify progression into expensive confirmatory trials.
What must happen before Gilead Sciences can turn HCXT-2001 into a commercial IBD therapy?
The first near-term milestone is completion of the transaction, which Gilead expects during the fourth quarter of 2026. Until the agreement closes, the acquired programme remains subject to the transaction’s conditions. The financial effects and integration of the development assets will become clearer following completion.
The subsequent clinical challenge is to establish a credible human safety and pharmacology profile for HCXT-2001. Results from early studies will help determine whether the molecule can progress into appropriately designed trials in inflammatory bowel disease. Those studies will need to demonstrate more than biological target engagement before the programme can be considered clinically competitive.
Emvistegrast’s planned Phase 3 development introduces a parallel opportunity that is more advanced but still carries regulatory uncertainty. Its Phase 2 results provide an encouraging foundation, yet larger studies will need to establish whether clinical benefits are reproducible and sufficiently durable. Any combination involving HCXT-2001 would require its own evidence rather than relying on emvistegrast monotherapy findings.
The competitive position of oral IL-23 receptor inhibitors will continue evolving as approved and investigational products generate additional clinical data. Johnson & Johnson’s existing icotrokinra approval establishes an important precedent in psoriasis, but IBD remains a distinct development challenge for oral IL-23-targeted medicines. Gilead’s success will depend on producing evidence relevant to intestinal disease rather than transferring expectations from other indications.
The $1.275 billion purchase price demonstrates Gilead’s willingness to invest substantially in an emerging inflammation programme. Its eventual value, however, will be determined by the progression of HCXT-2001 from Phase 1 investigation into clinical studies capable of establishing meaningful treatment benefits. The acquisition gives Gilead another mechanism to pursue, but the central question remains whether the molecule can deliver an efficacy, safety and convenience profile compelling enough to justify its place in inflammatory bowel disease treatment.
